Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 Jul 1;49(7):1182-1186.
doi: 10.1097/CCM.0000000000005068.

Convalescent Plasma and Coronavirus Disease 2019: Time for Reassessment

Daniel A Sweeney  1 , Constance A Benson  2 , Andre C Kalil  3
Affiliations
Editorial

Convalescent Plasma and Coronavirus Disease 2019: Time for Reassessment

Daniel A Sweeney et al. Crit Care Med. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Dr. Benson's institution received funding from the National Institutes of Health (NIH) and Gilead; she received funding from GlaxoSmithKline, ViiV Healthcare, IAS-USA, and Infectious Diseases Society of America; and she received support for article research from the NIH. The remaining authors have disclosed that they do not have any potential conflicts of interest.

Comment on

  • Severe Acute Respiratory Syndrome Coronavirus 2 Convalescent Plasma Versus Standard Plasma in Coronavirus Disease 2019 Infected Hospitalized Patients in New York: A Double-Blind Randomized Trial.
    Bennett-Guerrero E, Romeiser JL, Talbot LR, Ahmed T, Mamone LJ, Singh SM, Hearing JC, Salman H, Holiprosad DD, Freedenberg AT, Carter JA, Browne NJ, Cosgrove ME, Shevik ME, Generale LM, Andrew MA, Nachman S, Fries BC; Stony Brook Medicine COVID Plasma Trial Group; Stony Brook Medicine COVID Plasma Trial Group are as follows: Investigators; Principal Investigator, Critical Care; Pathology/Blood Bank; Infectious Disease; Safety Monitor; Biostatistics; Hematology; (Blood Bank; and; Pathology, Laboratory Services). Team 1 (Online Survey/In Person Scheduling); Team Leader; and; Team 2 (In Person Screening Visits); Team Leader; and; Team 3 (Patient/Recipient Screening, Plasma Administration, Data Capture); Team Leader; and; and; and; and; Team M (Antibody Testing/Randomization):; Team Leader; and; Plaque Reduction Neutralization Assay: Janet Hearing. Regulatory (Investigational New Drug [IND] and Institutional Review Board [IRB] support); (IND support); (IRB support), and; Data and Safety Monitoring Board (DSMB); and; (Chair) and; (unblinded DSMB statistician); Stony Brook Medicine COVID Plasma Trial Group and Stony Brook Medicine COVID Plasma Trial Group are as follows: Investigators a… See abstract for full author list ➔ Bennett-Guerrero E, et al. Crit Care Med. 2021 Jul 1;49(7):1015-1025. doi: 10.1097/CCM.0000000000005066. Crit Care Med. 2021. PMID: 33870923 Free PMC article. Clinical Trial.

References

    1. U.S. Food and Drug Administration. FDA News Release: FDA Issues Emergency Use Authorization for Convalescent Plasma as Potential Promising COVID–19 Treatment, Another Achievement in Administration’s Fight Against Pandemic. 2020. Available at: https://www.fda.gov/news-events/press-announcements/fda-issues-emergency... . Accessed March 6, 2021
    1. U.S. Food and Drug Administration. FDA In Brief: FDA Updates Emergency Use Authorization for COVID-19 Convalescent Plasma to Reflect New Data. 2020. Available at: https://www.fda.gov/news-events/fda-brief/fda-brief-fda-updates-emergenc... . Accessed March 2, 2021
    1. Bennett-Guerrero E, Romeiser JL, Talbot LR, et al.; Stony Brook Medicine COVID Plasma Trial Group. Severe Acute Respiratory Syndrome Coronavirus 2 Convalescent Plasma Versus Standard Plasma in Coronavirus Disease 2019 Infected Hospitalized Patients in New York: A Double-Blind Randomized Trial. Crit Care Med. 2021; 49:1015–1025
    1. Agarwal A, Mukherjee A, Kumar G, et al.; PLACID Trial Collaborators: Convalescent plasma in the management of moderate COVID-19 in adults in India: Open label phase II multicentre randomised controlled trial (PLACID Trial). BMJ. 2020; 371:m3939
    1. AlQahtani M, Abdulrahman A, Almadani A, et al. Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease. medRxiv. 2020.11.02.20224303